Your alter ego "kmife" says a t-reg deal is imminent (before Sept). Maybe "kmife" will be right for the first time ever ;-)
Fabry gene therapy looks much more promising than hemo A. Protocols amendments by both Sangamo and 4DMT have opened the Fabry trials up to females, which is unusual in the gene therapy space. That suggests to me it's really working well and we'll see this through to market. Pfizer may either partner with 4DMT or buyout 4DMT completely. I see FDMT making a major move on such news. Sangamo is and always has been operating in survival mode, adding to its backup arsenal t-regs, base and mitochondrial gene editing. I think with encouraging Fabry data (which I expect) and a new partnership deal in t-regs or base editing we'll see $10 by YE. I'm guessing Hemo A will be left in neutral until it stalls out later this year, and then based on the outcome of Roctavian trials and filing outcome, will be rejiggered by Pfizer into a completely new trial, or abandoned.